Biodexa Pharma Partners With Syngene International To Manufacture Both MTX240 Active Pharmaceutical Ingredient And Dosage Form

MIDATECH PHARMA PLC SPON ADS EACH REP 5 ORD -7.41% Pre

MIDATECH PHARMA PLC SPON ADS EACH REP 5 ORD

BDRX

3.25

3.36

-7.41%

+3.36% Pre

Biodexa Announces Partnership with Syngene

To Manufacture MTX240 GMP Clinical Trial Supplies

Biodexa Pharmaceuticals PLC (NASDAQ:BDRX) ("Biodexa" or "Company"), a clinical stage biopharmaceutical company developing a clinical stage biopharmaceutical company developing innovative products focused on the treatment or prevention of gastrointestinal cancers, is pleased to announce that it has partnered with Syngene International Ltd (BSE: 539268, NSE: SYNGENE) ("Syngene") for the manufacture of both MTX240 active pharmaceutical ingredient and dosage form.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.